DE2611824C2 - - Google Patents

Info

Publication number
DE2611824C2
DE2611824C2 DE2611824A DE2611824A DE2611824C2 DE 2611824 C2 DE2611824 C2 DE 2611824C2 DE 2611824 A DE2611824 A DE 2611824A DE 2611824 A DE2611824 A DE 2611824A DE 2611824 C2 DE2611824 C2 DE 2611824C2
Authority
DE
Germany
Prior art keywords
general formula
dihydro
mixture
methyl
oxoquinol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2611824A
Other languages
German (de)
English (en)
Other versions
DE2611824A1 (de
Inventor
David Robert Brittain
Edward Douglas Brown
Walter Hepworth
Gilbert Joseph Macclesfield Cheshire Gb Stacey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial Chemical Industries Ltd
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB11644/75A external-priority patent/GB1502312A/en
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Publication of DE2611824A1 publication Critical patent/DE2611824A1/de
Application granted granted Critical
Publication of DE2611824C2 publication Critical patent/DE2611824C2/de
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DE19762611824 1975-03-20 1976-03-19 Chinolonderivate Granted DE2611824A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB11644/75A GB1502312A (en) 1975-03-20 1975-03-20 Quinolone derivatives
GB4204375 1975-10-14

Publications (2)

Publication Number Publication Date
DE2611824A1 DE2611824A1 (de) 1976-09-30
DE2611824C2 true DE2611824C2 (enExample) 1987-06-19

Family

ID=26248416

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19762611824 Granted DE2611824A1 (de) 1975-03-20 1976-03-19 Chinolonderivate

Country Status (19)

Country Link
US (1) US4066651A (enExample)
JP (1) JPS51118773A (enExample)
AU (1) AU1147676A (enExample)
CS (1) CS188273B2 (enExample)
DD (1) DD124117A5 (enExample)
DE (1) DE2611824A1 (enExample)
DK (1) DK115376A (enExample)
ES (1) ES446234A1 (enExample)
FI (1) FI760729A7 (enExample)
FR (1) FR2304342A1 (enExample)
HU (1) HU172032B (enExample)
IE (1) IE43079B1 (enExample)
IL (1) IL49126A0 (enExample)
LU (1) LU74594A1 (enExample)
NL (1) NL7602834A (enExample)
NO (1) NO760993L (enExample)
PT (1) PT64921B (enExample)
SE (1) SE434394B (enExample)
SU (1) SU648090A3 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964973B2 (en) 1999-08-27 2005-11-15 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US5225402A (en) * 1989-02-10 1993-07-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
EP0382185B1 (en) * 1989-02-10 1994-06-15 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
DE69128481T2 (de) * 1990-09-07 1998-04-09 Schering Corp Antivirale und antihypertensive verbindungen
TW198715B (enExample) * 1991-04-19 1993-01-21 Dtsuka Seiyaku Kk
DE69207560T2 (de) * 1991-06-07 1996-06-27 Otsuka Pharma Co Ltd Antidiabetikum
DE19839499A1 (de) * 1998-08-29 2000-03-02 Merck Patent Gmbh 2-Oxo-2H-chinolinderivate
JP2003508402A (ja) * 1999-08-27 2003-03-04 リガンド・ファーマシューティカルズ・インコーポレイテッド アンドロゲン受容体モジュレーター化合物および方法
AU6941200A (en) 1999-08-27 2001-03-26 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido(3,2-g)quinoline compounds as androgen receptor modulators
EP1216221A2 (en) 1999-09-14 2002-06-26 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
FR2811912B1 (fr) * 2000-07-21 2003-02-07 Gattefosse Ets Sa Procede d'enrobage de particules solides par un agent thermofusible, et particules solides ainsi enrobees
MXPA06001751A (es) * 2003-08-22 2006-05-12 Ligand Pharm Inc Derivados de 6-cicloamino-2-quinolinona como compuestos moduladores de receptor de androgeno.
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI417095B (zh) * 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) * 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
AU2008297877C1 (en) * 2007-09-14 2013-11-07 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones
EP2203439B1 (en) * 2007-09-14 2011-01-26 Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-ý1, 4'¨bipyridinyl-2'-ones
CN101848893B (zh) 2007-09-14 2012-06-06 奥梅-杨森制药有限公司 1,3-二取代的4-(芳基-x-苯基)-1h-吡啶-2-酮
CN101861316B (zh) * 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
WO2009062309A1 (en) * 2007-11-15 2009-05-22 Universite Laval Methods for the regulation of the prostaglandin f synthase (pgfs) activity of akr1b1 and uses thereof
MX2011002042A (es) 2008-09-02 2011-06-20 Ortho Mcneil Janssen Pharm Derivados de 3-azabiciclo[3.1.o]hexilo como moduladores de los receptores del glutamato metabotropico.
ES2466341T3 (es) 2008-10-16 2014-06-10 Janssen Pharmaceuticals, Inc. Derivados de indol y benzomorfolina como moduladores de receptores de glutamato metabotrópicos
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2430022B1 (en) 2009-05-12 2013-11-20 Janssen Pharmaceuticals, Inc. 1,2,4-Triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
JP5707390B2 (ja) 2009-05-12 2015-04-30 ジャンセン ファーマシューティカルズ， インコーポレイテッド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体の正のアロステリック調節因子としてのその使用
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2012062750A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
AU2015208233B2 (en) 2014-01-21 2019-08-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3772301A (en) * 1971-11-22 1973-11-13 Warner Lambert Co (4-substituted)4-(methylsulfinyl)methylcarbostyrils

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964973B2 (en) 1999-08-27 2005-11-15 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US7696246B2 (en) 1999-08-27 2010-04-13 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods

Also Published As

Publication number Publication date
LU74594A1 (enExample) 1977-05-06
DD124117A5 (enExample) 1977-02-02
IE43079L (en) 1976-09-20
JPS51118773A (en) 1976-10-18
DK115376A (da) 1976-09-21
PT64921B (en) 1977-08-24
NO760993L (enExample) 1976-09-21
HU172032B (hu) 1978-05-28
IL49126A0 (en) 1976-05-31
ES446234A1 (es) 1977-10-01
DE2611824A1 (de) 1976-09-30
SE7602339L (sv) 1976-09-21
NL7602834A (nl) 1976-09-22
FR2304342B1 (enExample) 1979-09-21
AU1147676A (en) 1977-09-01
FR2304342A1 (fr) 1976-10-15
PT64921A (en) 1976-04-01
SE434394B (sv) 1984-07-23
JPH0122267B2 (enExample) 1989-04-25
IE43079B1 (en) 1980-12-17
CS188273B2 (en) 1979-02-28
FI760729A7 (enExample) 1976-09-21
US4066651A (en) 1978-01-03
SU648090A3 (ru) 1979-02-15

Similar Documents

Publication Publication Date Title
DE2611824C2 (enExample)
AT390257B (de) Verfahren zur herstellung neuer imidazo(4,5-b)chinolin-derivate
DE2560549C2 (enExample)
EP0004279B1 (de) Verfahren zur Herstellung von 4-Pyridon-3-carbonsäuren, 1-Cyclopropyl-4-Pyridon-3-Carbonsäurederivate und diese enthaltende Arzneimittel
DE2103805A1 (de) Verfahren zur Herstellung einer antibakteriell wirksamen Verbindung und Zwischenprodukte hierfür
DE3011994C2 (enExample)
DE2134146A1 (de) Tetrazolo(l,5-a)chinolineenthaltende Mittel zur Bekämpfung von pflanzenpathogenen Organismen
DE2141634A1 (de) Neue Isoindolinderivate, ihre Herstellung und Zusammensetzungen, die diese enthalten
DD253823A5 (de) Verfahren zur herstellung neuartiger thienopyridone
EP0258729A2 (de) Dihydropyridinverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung
DE2453977A1 (de) Neue ferrocen verbindungen und verfahren zu deren herstellung sowie pharmazeutische zusammensetzungen
EP0386628B1 (de) Verfahren zur Herstellung von Indolcarbonsäurederivaten
DE2504250A1 (de) Tetrahydroisochinolin-derivate und verfahren zu ihrer herstellung
DE69720966T2 (de) Benzo[c]chinolizin derivate,deren herstellung und verwendung als 5-alfa-reduktase inhibitoren
DE2006472A1 (de) Furan-3-carboxamid-Derivate und Verfahren zu ihrer Herstellung
DE2344799A1 (de) Schwefelhaltige tricyclische verbindungen und diese enthaltende arzneimittel
EP0072960B1 (de) 1,5-Diphenylpyrazolin-3-on-Verbindungen sowie Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE3911064A1 (de) Substituierte 1,8-naphthyridine
DE3038593C2 (enExample)
DE2841644C2 (enExample)
DE3138121A1 (de) Chinolone, verfahren zur ihrer herstellung und ihre verwendung in therapeutischen zubereitungen
DE3300522C2 (enExample)
DE1668958B2 (de) Verfahren zur herstellung von dichlorchinolinen
DE2818290A1 (de) Neue naphthyridine
EP0004322A1 (de) Isochinolinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneimitteln

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee